BRIEF—Fuji Pharma to sell Alvotech biosimilars in Japan

Reykjavik-based Alvotech has agreed a commercialization deal with Fuji Pharma to sell its biosimilar portfolio in Japan.

Under the terms of the deal, Alvotech will develop and supply biosimilars from its current pipeline, while Fuji will register and sell them in Japan.

Alvotech is working on biosimilars in oncology, ophthalmology and autoimmune diseases.

Fuji chief executive Eiji Takamasa said: “Fuji Pharma’s strong market reach in Japan, complemented with Alvotech’s futuristic portfolio of the expected first-to-launch biosimilar products, will provide the critical synergies for the success of this partnership.”